Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 313

  • 3 926 clinical trials
  • 1 543 recruiting
  • 706 conditions
  • 31 countries

Conditions in this area

706 conditions with trials, the busiest first

Non-small cell lung cancer332Breast cancer170Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic106Prostate cancer102Colorectal cancer90Ovarian cancer90Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Chronic lymphocytic leukaemia80Malignant melanoma79Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV59Pancreatic carcinoma57Hormone-refractory prostate cancer56Bladder cancer55Gastric cancer55Endometrial cancer53+682

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 926 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 926 clinical trials

Head and neck cancer

Not recruiting

Study of Radiotherapy with Cetuximab and Xevinapant for Patients with Advanced Head and Neck Cancer Unfit for High-Dose Cisplatin

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Renal cell carcinoma

Not recruiting

Study of Pembrolizumab and Lenvatinib for Patients with Advanced Non-Clear Cell Kidney Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Merck Sharp & Dohme LLC

Neoplasm

Not recruiting

Study of Olaparib and Pembrolizumab for Patients with Advanced Cancer with HRRm or HRD Mutations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:Merck Sharp & Dohme LLC

Hormone-refractory prostate cancer+1

Not recruiting

Study of Nivolumab, Ipilimumab, or Cabazitaxel for Men with Advanced Prostate Cancer Resistant to Hormone Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cabazitaxel
  • Sponsor:Bristol Myers Squibb International Corporation

Chronic rhinosinusitis with nasal polyps

Not recruiting

Study on Secukinumab for Treating Chronic Rhinosinusitis with Nasal Polyps in Non-Type 2 Patients

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years
  • Substances:Secukinumab
  • Sponsor:Tartu University Hospital

Breast cancer

Not recruiting

Study on the Safety and Antitumor Activity of ARV-471 and Ribociclib in Adults with ER+ Advanced or Metastatic Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ribociclib
  • Sponsor:Pfizer Inc.

Cholangiocarcinoma+1

Not recruiting

Study on the Safety of LSTA1 with Standard Care for Patients with Advanced Head and Neck Cancer or Cholangiocarcinoma

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Lisata Therapeutics Inc.

Breast cancer

Not recruiting

Study on the Safety and Antitumor Effects of Vepdegestrant and Abemaciclib in Adults with ER+ Advanced or Metastatic Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Pfizer Inc.

Marginal zone lymphoma+1

Not recruiting

Study Comparing Zanubrutinib, Obinutuzumab, and Rituximab with Lenalidomide and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:BeOne Medicines AG

Metastases to liver

Not recruiting

Study on Fluorescence-Guided Surgery for Colorectal Liver Metastases Using SGM-101 and Indocyanine Green for Patients with Colorectal Cancer

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Chimeric Monoclonal Antibody Against Carcinoembryonic Antigen Conjugated To Fluorochrome Bm-104
  • Sponsor:Leiden University Medical Center

Hodgkin's disease

Not recruiting

Study of Relatlimab and Nivolumab for Children and Young Adults with Recurrent or Refractory Hodgkin and Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Breast cancer metastatic+1

Not recruiting

Study of Trastuzumab Deruxtecan for Patients with HER2-Positive Metastatic Breast Cancer Resistant to Trastuzumab, Pertuzumab, and Taxane Treatment

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer De Mama

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab467 clinical trialsCarboplatin344 clinical trialsCisplatin288 clinical trialsPaclitaxel266 clinical trialsFluorouracil239 clinical trialsOxaliplatin230 clinical trialsNivolumab218 clinical trialsDexamethasone169 clinical trialsDurvalumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.